These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 24633632)

  • 1. Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.
    Kaplan N; Vituri A; Korczyn AD; Cohen OS; Inzelberg R; Yahalom G; Kozlova E; Milgrom R; Laitman Y; Friedman E; Rosset S; Hassin-Baer S
    J Mol Neurosci; 2014 Jun; 53(2):183-8. PubMed ID: 24633632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DAT gene polymorphisms (rs28363170, rs393795) and levodopa-induced dyskinesias in Parkinson's disease.
    Purcaro C; Vanacore N; Moret F; Di Battista ME; Rubino A; Pierandrei S; Lucarelli M; Meco G; Fattapposta F; Pascale E
    Neurosci Lett; 2019 Jan; 690():83-88. PubMed ID: 30316985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study.
    Dos Santos EUD; da Silva IIFG; Asano AGC; Asano NMJ; De Mascena Diniz Maia M; de Souza PRE
    Mol Biol Rep; 2020 Nov; 47(11):8997-9004. PubMed ID: 33151475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene polymorphisms and motor levodopa-induced complications in Parkinson's disease.
    Michałowska M; Chalimoniuk M; Jówko E; Przybylska I; Langfort J; Toczylowska B; Krygowska-Wajs A; Fiszer U
    Brain Behav; 2020 Mar; 10(3):e01537. PubMed ID: 32022467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms of the dopamine metabolic and signaling pathways are associated with susceptibility to motor levodopa-induced complications (MLIC) in Parkinson's disease: a systematic review and meta-analysis.
    Soraya GV; Ulhaq ZS; Shodry S; A'raaf Sirojan Kusuma M; Herawangsa S; Sativa MO; Gustaf A; Faridwazdi DAN; Florentia SW; Raisa N; Bintang AK; Akbar M
    Neurol Sci; 2022 Jun; 43(6):3649-3670. PubMed ID: 35079903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease.
    Cheshire P; Bertram K; Ling H; O'Sullivan SS; Halliday G; McLean C; Bras J; Foltynie T; Storey E; Williams DR
    Neurodegener Dis; 2014; 13(1):24-8. PubMed ID: 24008922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
    Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
    Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease.
    Lee JY; Cho J; Lee EK; Park SS; Jeon BS
    Mov Disord; 2011 Jan; 26(1):73-9. PubMed ID: 20945430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between variants in levodopa metabolic pathway genes and levodopa-induced dyskinesia in Parkinson's disease.
    Yan JH; Ge YL; Wang PZ; Li W; Jin H; Zhang JR; Chen J; Wang F; Li D; Mao CJ; Li K; Liu CF
    Neurosci Lett; 2023 Mar; 801():137140. PubMed ID: 36813078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa-Induced Dyskinesia.
    Sosero YL; Bandres-Ciga S; Ferwerda B; Tocino MTP; Belloso DR; Gómez-Garre P; Faouzi J; Taba P; Pavelka L; Marques TM; Gomes CPC; Kolodkin A; May P; Milanowski LM; Wszolek ZK; Uitti RJ; Heutink P; van Hilten JJ; Simon DK; Eberly S; Alvarez I; Krohn L; Yu E; Freeman K; Rudakou U; Ruskey JA; Asayesh F; Menéndez-Gonzàlez M; Pastor P; Ross OA; Krüger R; ; Corvol JC; Koks S; Mir P; De Bie RMA; Iwaki H; Gan-Or Z;
    Mov Disord; 2024 Oct; 39(10):1773-1783. PubMed ID: 39132902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson's disease.
    Dos Santos EUD; Sampaio TF; Tenório Dos Santos AD; Bezerra Leite FC; da Silva RC; Crovella S; Asano AGC; Asano NMJ; de Souza PRE
    J Pharm Pharmacol; 2019 Feb; 71(2):206-212. PubMed ID: 30353564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease.
    Yoo HS; Chung SJ; Chung SJ; Moon H; Oh JS; Kim JS; Hong JY; Ye BS; Sohn YH; Lee PH
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):423-431. PubMed ID: 29075830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease.
    Foltynie T; Cheeran B; Williams-Gray CH; Edwards MJ; Schneider SA; Weinberger D; Rothwell JC; Barker RA; Bhatia KP
    J Neurol Neurosurg Psychiatry; 2009 Feb; 80(2):141-4. PubMed ID: 18977816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD.
    Oliveri RL; Annesi G; Zappia M; Civitelli D; Montesanti R; Branca D; Nicoletti G; Spadafora P; Pasqua AA; Cittadella R; Andreoli V; Gambardella A; Aguglia U; Quattrone A
    Neurology; 1999 Oct; 53(7):1425-30. PubMed ID: 10534246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's disease.
    Kusters CDJ; Paul KC; Guella I; Bronstein JM; Sinsheimer JS; Farrer MJ; Ritz BR
    Parkinsonism Relat Disord; 2018 Feb; 47():39-44. PubMed ID: 29191473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MTOR Pathway-Based Discovery of Genetic Susceptibility to L-DOPA-Induced Dyskinesia in Parkinson's Disease Patients.
    Martín-Flores N; Fernández-Santiago R; Antonelli F; Cerquera C; Moreno V; Martí MJ; Ezquerra M; Malagelada C
    Mol Neurobiol; 2019 Mar; 56(3):2092-2100. PubMed ID: 29992529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients.
    Rieck M; Schumacher-Schuh AF; Altmann V; Francisconi CL; Fagundes PT; Monte TL; Callegari-Jacques SM; Rieder CR; Hutz MH
    Pharmacogenomics; 2012 Nov; 13(15):1701-10. PubMed ID: 23171335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study.
    Zappia M; Annesi G; Nicoletti G; Arabia G; Annesi F; Messina D; Pugliese P; Spadafora P; Tarantino P; Carrideo S; Civitelli D; De Marco EV; Cirò-Candiano IC; Gambardella A; Quattrone A
    Arch Neurol; 2005 Apr; 62(4):601-5. PubMed ID: 15824260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the Side Onset of Parkinson's Disease Influence the Time to Develop Levodopa-Induced Dyskinesia?
    Chung SJ; Yoo HS; Lee HS; Lee PH; Sohn YH
    J Parkinsons Dis; 2019; 9(1):241-247. PubMed ID: 30741690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High levodopa plasma concentration after oral administration predicts levodopa-induced dyskinesia in Parkinson's disease.
    Shiraishi T; Nishikawa N; Mukai Y; Takahashi Y
    Parkinsonism Relat Disord; 2020 Jun; 75():80-84. PubMed ID: 32497995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.